查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1421656

陰道炎治療藥物市場、份額、規模、趨勢、行業分析報告：按疾病類型、產品、地區和細分市場預測，2023-2032 年

Vaginitis Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Anti-fungal, Anti-bacterial, Hormone); By Product (OTC, Prescription); By Region, And Segment Forecasts, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2032 年，全球陰道炎治療市場預計將達到 72 億美元。 該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

一些政府和非政府組織發起了一些計劃，以提高女性對陰道炎藥物的認識，從而導致對這些藥物的需求增加。 此外，飲酒趨勢預計將進一步推動這些藥物的採用。 約有 530 萬名女性面臨陰道炎帶來的健康相關問題的風險，尤其是在美國。

此外，對陰道炎治療藥物研發的日益關注預計將有助於市場成長。 由國家過敏和傳染病研究所 (NIAID) 等組織資助的各種研究為酵母菌的發育行為提供了寶貴的見解，這可能會帶來酵母菌感染的創新治療方法。 此外，主要製藥公司推出新藥預計將成為市場擴張的推動力，顯示該行業的積極趨勢。

益生菌療法最近引起了廣泛的研究興趣，部分原因是目前念珠菌陰道炎的治療結果並不令人滿意。 最常用於治療念珠菌陰道炎的抗黴菌藥物包括克黴唑、氟康唑、咪康唑和製黴菌素。 然而，其中一些藥物只能抑制真菌生長，但不能完全消滅真菌。 另外，長期使用可能會損害陰道正常細胞和組織，導致陰道局部微生物群失衡、酸鹼失衡、重複感染、反覆感染等。 因此，迫切需要探索能夠控制陰道微環境的念珠菌陰道炎治療方法。

功能分析結果表明，奈米□與透明質酸水凝膠相結合，即使在低過氧化氫濃度下也能有效消滅白色念珠菌。 將奈米□與乳酸菌結合，可顯著降低念珠菌陰道炎治療期間真菌存活率 70%。 相較之下，單獨使用乳酸菌並不影響真菌的存活。 詳細分析表明，奈米□和乳酸菌的結合可以極其有效地產生羥基自由基，對真菌細胞膜造成重大損害。 值得注意的是，這種聯合治療對乳酸菌沒有負面影響。

根據美國疾病管制與預防中心(CDC) 性傳染感染(STI) 治療指南，有症狀的BV 患者應口服甲硝唑，每日兩次，持續7 天，或陰道內注射，每日5天。或陰道給予克林黴素凝膠7天。 研究表明，口服甲硝唑可暫時改善 BV 復發患者的陰道微生物群，但治療後 30 天會復發。 其他研究表明，初始治療後陰道內苯並硝唑 (IBA) 和硝基咪唑治療的治癒率更高。

陰道炎治療藥物市場報告亮點

  • 由於產品範圍廣泛且細菌性陰道炎患者數量不斷增加，抗生素領域在市場上佔據主導地位
  • 由於產品管道的存在以及醫療從業者的採用，荷爾蒙產業預計將快速成長。
  • 北美在市場上佔據主導地位，這主要是由於陰道炎病例數量的增加和患者意識的提高。
  • 主要市場參與者包括輝瑞、默克、諾華、拜耳、Lupin Pharmaceuticals、Symbiomics Therapeutics 和 Mission Pharmaceuticals。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第四章全球陰道炎治療藥物市場洞察

  • 陰道炎治療藥物市場 - 產業概況
  • 陰道炎治療藥物市場動態
    • 推動者和機會
      • 提高婦女健康意識與教育
      • 診斷和治療方案的技術進步
    • 抑制因素和挑戰
      • 對抗生素和抗真菌藥物的抗藥性
  • 杵分析
  • 陰道炎治療藥物產業的趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第五章全球陰道炎治療藥物市場（依疾病類型）

  • 主要發現
  • 簡介
  • 抗黴菌劑
  • 抗菌
  • 荷爾蒙

第 6 章全球陰道炎治療藥物市場，分產品

  • 主要發現
  • 簡介
  • 非處方藥 (OTC)
  • 處方

第 7 章全球陰道炎治療藥物市場（按地區）

  • 主要發現
  • 簡介
    • 2019-2032 年陰道炎治療藥物市場評估（按地區）
  • 陰道炎治療藥物市場 - 北美
    • 北美：陰道炎治療藥物市場，按產品，2019-2032 年
    • 北美：陰道炎治療藥物市場，依疾病類型，2019-2032 年
    • 陰道炎治療藥物市場 - 美國
    • 陰道炎治療藥物市場 - 加拿大
  • 陰道炎治療藥物市場 - 歐洲
    • 歐洲：陰道炎治療藥物市場，按產品，2019-2032 年
    • 歐洲：陰道炎治療藥物市場，依疾病類型，2019-2032 年
    • 陰道炎治療藥物市場 - 英國
    • 陰道炎治療藥物市場－法國
    • 陰道炎治療藥物市場—德國
    • 陰道炎治療藥物市場—義大利
    • 陰道炎治療藥物市場 - 西班牙
    • 陰道炎治療藥物市場 - 荷蘭
    • 陰道炎治療藥物市場 - 俄羅斯
  • 陰道炎治療藥物市場 - 亞太地區
    • 亞太地區：陰道炎治療藥物市場，按產品，2019-2032 年
    • 亞太地區：陰道炎治療藥物市場，依疾病類型，2019-2032 年
    • 陰道炎治療藥物市場 - 中國
    • 陰道炎治療藥物市場 - 印度
    • 陰道炎治療藥物市場 - 馬來西亞
    • 陰道炎治療藥物市場 - 日本
    • 陰道炎治療藥物市場 - 印尼
    • 陰道炎治療藥物市場－韓國
  • 陰道炎治療藥物市場 - 中東和非洲
    • 中東和非洲：陰道炎治療藥物市場，按產品，2019-2032 年
    • 中東和非洲：陰道炎治療藥物市場，按疾病類型，2019-2032 年
    • 陰道炎治療藥物市場 - 沙烏地阿拉伯
    • 陰道炎治療藥物市場 - 阿拉伯聯合大公國
    • 陰道炎治療藥物市場 - 以色列
    • 陰道炎治療藥物市場 - 南非
  • 陰道炎治療藥物市場 - 拉丁美洲
    • 拉丁美洲：陰道炎治療藥物市場，按產品，2019-2032 年
    • 拉丁美洲：陰道炎治療藥物市場，依疾病類型，2019-2032 年
    • 陰道炎治療藥物市場 - 墨西哥
    • 陰道炎治療藥物市場 - 巴西
    • 陰道炎治療藥物市場 - 阿根廷

第 8 章競爭態勢

  • 擴張與收購分析
    • 擴大
    • 收購
  • 夥伴關係/協作/協議/揭露

第 9 章公司簡介

  • Pfizer, Inc.
  • Merck & Co.
  • Novartis AG
  • Bayer AG
  • Lupin Pharmaceuticals, Inc.
  • Symbiomix Therapeutics, Inc.
  • Mission Pharmacal Company
Product Code: PM3987

The global vaginitis therapeutics market size is expected to reach USD 7.20 billion by 2032, according to a new study by Polaris Market Research. The report "Vaginitis Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Anti-fungal, Anti-bacterial, Hormone); By Product (OTC, Prescription); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Several organizations, both governmental and non-governmental, have initiated programs aimed at creating awareness among women regarding vaginitis drugs, which has led to an increased demand for these drugs. Furthermore, the rising trend of alcohol consumption is expected to further boost the adoption of these drugs. Notably, in the United States, about 5.3 million women are at risk of health-related issues due to vaginitis.

In addition, the increasing focus on research and development of vaginitis therapeutics is expected to contribute to the growth of the market. Various studies funded by organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) have yielded valuable insights into yeast generative behavior, which could lead to innovative treatment approaches for yeast infections. Moreover, the introduction of new medications by major pharmaceutical companies is projected to drive the market expansion, indicating a positive trend for the industry.

Probiotic therapy has gained significant research attention recently, in part due to the unsatisfactory outcomes of current treatments for Candida vaginitis. The most commonly used antifungal drugs for Candida vaginitis include Clotrimazole, Fluconazole, Miconazole, and Nystatin. However, some of these drugs only inhibit fungal growth without eradicating them entirely. Prolonged use can also harm normal vaginal cells and tissues, leading to imbalances in local vaginal microbiota, disruptions in acid-base balance, superinfections, and recurrent infections. Therefore, there is an urgent need to explore therapies for Candida vaginitis that can regulate the vaginal microenvironment.

Functional analysis has shown that when hyaluronic acid hydrogel is combined with nanozymes, it effectively eradicates Candida albicans even at lower hydrogen peroxide concentrations. Combining nanozymes with Lactobacillus led to a significant 70% reduction in fungal viability during Candida vaginitis treatment. In contrast, using Lactobacillus alone did not demonstrate any impact on fungal viability. In-depth analysis demonstrated that the joint application of nanozymes and Lactobacillus is remarkably efficient in producing hydroxyl radicals, causing substantial damage to the fungal cell membrane. Notably, this combination treatment did not adversely affect the Lactobacillus bacteria.

According to the Centers for Disease Control and Prevention (CDC), symptomatic BV patients should be treated with metronidazole, either orally twice a day for seven days, intravaginally daily for five days, or clindamycin gel intravaginally for seven days, as per their guidelines on sexually transmitted infections (STI) treatment. Research has shown that oral metronidazole provides temporary improvement in the vaginal microbiome for recurrent BV patients, but recurrence occurs by day 30 after therapy. Another study indicated that after initial treatment, the cure rate with Intravaginal Benznidazole (IBA) and nitroimidazole therapy was higher.

Vaginitis Therapeutics Market Report Highlights

  • The anti-bacterial segment dominated the market owing to the availability of a wide product range and rising number of bacterial vaginosis cases
  • The hormone segment will grow at a rapid pace due to the presence of a pipeline of products and adoption among medical practitioners
  • North America dominated the market, primarily due to rising cases of vaginitis and awareness among patient
  • The key market players include Pfizer, Merck, Novartis, Bayer, Lupin Pharmaceuticals, Symbiomix Therapeutics, and Mission Pharmacal.

Polaris Market Research has segmented the vaginitis therapeutics market report based on disease type, product, and region:

Viginitis Therapeutics, Disease Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Anti-fungal
  • Anti-bacterial
  • Hormone

Viginitis Therapeutics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

  • Over-the-counter (OTC)
  • Prescription

Viginitis Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Vaginitis Therapeutics Market Insights

  • 4.1. Vaginitis Therapeutics Market - Industry Snapshot
  • 4.2. Vaginitis Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing awareness and education on women's health
      • 4.2.1.2. Technological advancements in diagnosis and treatment options
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Resistance to antibiotics and antifungal medications
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Vaginitis Therapeutics Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Vaginitis Therapeutics Market, by Disease Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Vaginitis Therapeutics, by Disease Type, 2019-2032 (USD Billion)
  • 5.3. Anti-fungal
    • 5.3.1. Global Vaginitis Therapeutics Market, by Anti-fungal, by Region, 2019-2032 (USD Billion)
  • 5.4. Anti-bacterial
    • 5.4.1. Global Vaginitis Therapeutics Market, by Anti-bacterial, by Region, 2019-2032 (USD Billion)
  • 5.5. Hormone
    • 5.5.1. Global Vaginitis Therapeutics Market, by Hormone, by Region, 2019-2032 (USD Billion)

6. Global Vaginitis Therapeutics Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 6.3. Over-the-counter (OTC)
    • 6.3.1. Global Vaginitis Therapeutics Market, by Over-the-counter (OTC), by Region, 2019-2032 (USD Billion)
  • 6.4. Prescription
    • 6.4.1. Global Vaginitis Therapeutics Market, by Prescription, by Region, 2019-2032 (USD Billion)

7. Global Vaginitis Therapeutics Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Vaginitis Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Vaginitis Therapeutics Market - North America
    • 7.3.1. North America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.2. North America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.3.3. Vaginitis Therapeutics Market - U.S.
      • 7.3.3.1. U.S.: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.3.4. Vaginitis Therapeutics Market - Canada
      • 7.3.4.1. Canada: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.4. Vaginitis Therapeutics Market - Europe
    • 7.4.1. Europe: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.3. Vaginitis Therapeutics Market - UK
      • 7.4.3.1. UK: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.4. Vaginitis Therapeutics Market - France
      • 7.4.4.1. France: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.5. Vaginitis Therapeutics Market - Germany
      • 7.4.5.1. Germany: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.6. Vaginitis Therapeutics Market - Italy
      • 7.4.6.1. Italy: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.7. Vaginitis Therapeutics Market - Spain
      • 7.4.7.1. Spain: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.8. Vaginitis Therapeutics Market - Netherlands
      • 7.4.8.1. Netherlands: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.9. Vaginitis Therapeutics Market - Russia
      • 7.4.9.1. Russia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.5. Vaginitis Therapeutics Market - Asia Pacific
    • 7.5.1. Asia Pacific: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.3. Vaginitis Therapeutics Market - China
      • 7.5.3.1. China: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.4. Vaginitis Therapeutics Market - India
      • 7.5.4.1. India: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.5. Vaginitis Therapeutics Market - Malaysia
      • 7.5.5.1. Malaysia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.6. Vaginitis Therapeutics Market - Japan
      • 7.5.6.1. Japan: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.7. Vaginitis Therapeutics Market - Indonesia
      • 7.5.7.1. Indonesia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.8. Vaginitis Therapeutics Market - South Korea
      • 7.5.8.1. South Korea: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.6. Vaginitis Therapeutics Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.6.3. Vaginitis Therapeutics Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.6.4. Vaginitis Therapeutics Market - UAE
      • 7.6.4.1. UAE: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.6.5. Vaginitis Therapeutics Market - Israel
      • 7.6.5.1. Israel: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.6.6. Vaginitis Therapeutics Market - South Africa
      • 7.6.6.1. South Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.7. Vaginitis Therapeutics Market - Latin America
    • 7.7.1. Latin America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.7.3. Vaginitis Therapeutics Market - Mexico
      • 7.7.3.1. Mexico: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.7.4. Vaginitis Therapeutics Market - Brazil
      • 7.7.4.1. Brazil: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.7.5. Vaginitis Therapeutics Market - Argentina
      • 7.7.5.1. Argentina: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Pfizer, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Merck & Co.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Novartis AG
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bayer AG
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Lupin Pharmaceuticals, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Symbiomix Therapeutics, Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Mission Pharmacal Company
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development

List of Tables

  • Table 1 Global Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 2 Global Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 3 Vaginitis Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 5 North America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 7 U.S.: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 8 Canada: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 9 Canada: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 10 Europe: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 11 Europe: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 12 UK: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 13 UK: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 14 France: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 15 France: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 16 Germany: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 17 Germany: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 18 Italy: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 19 Italy: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 20 Spain: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 21 Spain: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 24 Russia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 25 Russia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 28 China: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 29 China: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 30 India: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 31 India: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 34 Japan: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 35 Japan: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 39 South Korea: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 44 UAE: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 45 UAE: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 46 Israel: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 47 Israel: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 49 South Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 51 Latin America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 53 Mexico: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 55 Brazil: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 57 Argentina: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Vaginitis Therapeutics Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Product
  • Figure 7 Global Vaginitis Therapeutics Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Disease Type
  • Figure 9 Global Vaginitis Therapeutics Market, by Disease Type, 2022 & 2032 (USD Billion)
  • Figure 10 Vaginitis Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Vaginitis Therapeutics Market